These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 10785985)
41. Using clinical guidelines to assess the potential value of laboratory medicine in clinical decision-making. Hicks AJ; Carwardine ZL; Hallworth MJ; Kilpatrick ES Biochem Med (Zagreb); 2021 Feb; 31(1):010703. PubMed ID: 33380890 [TBL] [Abstract][Full Text] [Related]
45. Recommendations for lipid testing and reporting by Australian pathology laboratories. ; Appleton CA; Caldwell G; McNeil A; Meerkin M; Sikaris K; Sullivan DR; Thomas DW; Tognarini DP Clin Biochem Rev; 2007 May; 28(2):32-45. PubMed ID: 17687413 [TBL] [Abstract][Full Text] [Related]
46. Lipid management guidelines--2001. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. ; Med J Aust; 2001 Nov; 175(S2):S62-85. PubMed ID: 11758552 [No Abstract] [Full Text] [Related]
48. The lipid risk factor in hypertension and cardiovascular disease. Castelli WD Br J Clin Pharmacol; 1987; 24 Suppl 1(Suppl 1):59S-60S. PubMed ID: 3440109 [No Abstract] [Full Text] [Related]
49. [The involvement of biologically active lipids in cardiovascular pharmacotherapy]. Nechifor M Rev Med Chir Soc Med Nat Iasi; 1992; 96(1-2):29-30. PubMed ID: 1410919 [No Abstract] [Full Text] [Related]
50. [Physico-chemical investigation of blood components using special fluorescent probes]. Dobretsov GE Vestn Ross Akad Med Nauk; 2009; (10):15-9. PubMed ID: 20050071 [TBL] [Abstract][Full Text] [Related]
53. National Heart Foundation Cholesterol Review. Proceedings of a round table discussion. 31 August 1993. Sydney, Australia. Aust N Z J Med; 1994 Feb; 24(1):81-132. PubMed ID: 7911657 [No Abstract] [Full Text] [Related]
54. Heaven can wait… for lipid control in very high cardiovascular risk patients. Mello E Silva A Rev Port Cardiol (Engl Ed); 2021 Sep; 40(9):649-651. PubMed ID: 34503702 [No Abstract] [Full Text] [Related]
55. Risk-factor levels and the MONICA study. Flaherty GN Med J Aust; 1988 May; 148(10):538. PubMed ID: 3367823 [No Abstract] [Full Text] [Related]
56. Investigation of lipids. What do the results really mean? Sullivan D Aust Fam Physician; 2000 Mar; 29(3):207-11. PubMed ID: 10785985 [TBL] [Abstract][Full Text] [Related]
57. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645 [TBL] [Abstract][Full Text] [Related]
58. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Lozano JV; Pallarés V; Cea-Calvo L; Llisterri JL; Fernández-Pérez C; Martí-Canales JC; Aznar J; Gil-Guillén V; Redón J; Curr Med Res Opin; 2008 Mar; 24(3):659-70. PubMed ID: 18218194 [TBL] [Abstract][Full Text] [Related]
59. Total and regional fat and serum cardiovascular disease risk factors in lean and obese children and adolescents. Teixeira PJ; Sardinha LB; Going SB; Lohman TG Obes Res; 2001 Aug; 9(8):432-42. PubMed ID: 11500523 [TBL] [Abstract][Full Text] [Related]
60. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C; Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]